Immune Suppression and Tumor Growth
- George Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA, U.S.A.
- Elizabeth Jaffee, Department of Oncology, SKCCC, Johns Hopkins University, Baltimore, MD, U.S.A.
There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer, and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumor immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers with an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. View full description
Basic, translational, and clinical cancer researchers as well as practicing oncologists and their patients
- Published: July 2013
- Imprint: ACADEMIC PRESS
- ISBN: 978-0-12-394296-8
"...an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease."--Anticancer Research, January 2015 "Prendergast… and Jaffee…supply basic, translational, and clinical cancer researchers in immunology, biology, and pharmacology with 34 chapters on immunotherapy in cancer treatments. They address new principles of immune suppression in cancer and recent thinking in how immunotherapeutic and chemotherapeutic agents might be combined to defeat mechanisms of tumoral immune suppression and reprogram the inflammatory microenvironment of tumor cells to enhance long-term outcomes."--Reference & Research Book News, December 2013
Table of ContentsPart I: Principles of Cancer ImmunobiologyIntroductionCancer Immunoediting: From Immune Surveillance to Immune EscapeImmunosurveillance: Innate and Adaptive Anti-Tumor ImmunityCytokine Regulation of Immune Tolerance to TumorsImmunological Sculpting: Natural Killer Cell Receptors and LigandsImmune Escape: Immunosuppressive NetworksPart II: Cancer TherapeuticsCytotoxic Chemotherapy in Clinical Treatment of CancerTargeted Therapeutics in Cancer TreatmentConcepts in Pharmacology and ToxicologyCancer Immunotherapy: Challenges and OpportunitiesCancer VaccinesPart III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune SuppressionImmunotherapy and Cancer Therapeutics: Why Partner?Immune Stimulatory Features of Classical ChemotherapyDendritic Cells and Co-Inhibitory MoleculesRegulatory T Cells in Tumor Immunity: Role of Toll-like Receptors Tumor-associated Macrophages in Cancer Growth and ProgressionTumor-associated Myeloid-derived Suppressor CellsProgrammed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune EscapeIDO in Immune Escape: Regulation and Therapeutic InhibitionArginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune ModulationSummary: Future Questions